Ken Powell
Executive Chairman of the Board
Description:
Prior to his current role, Ken had very extensive experience of the Biotechnology sector. In reverse order he was: Executive Chairman of Q-Chip a Cardiff, Wales based life science company developing novel delayed release formulations of drugs (merged with Midatech and the joint company listed on AIM in 2015). Founder and CEO of Arrow Therapeutics Ltd (a specialised antiviral drug discovery company acquired by Astra-Zeneca PLC for $150 million in February 2007). Professor at UCL and Deputy Director of the Wolfson Institute for Biomedical Research where he had responsibility for commercial activity including setting up five biotechnology start-up companies. He was a senior Pharmaceutical executive with the Wellcome Foundation which he decided to leave at the Wellcome/Glaxo merger. He has had a successful academic career in the UK and USA. He is an expert virologist and has been involved in the development of multiple drugs including anti-viral compounds against herpes viruses, HIV, Hepatitis C and RSV.
Summary:
Prior to his current role, Ken had very extensive experience of the Biotechnology sector. In reverse order he was: Executive Chairman of Q-C...
Number of Registered Investments:1
Contact Details:
- Address: London, England, United Kingdom
- No email is provided
Location:London, England, United Kingdom
Email is Not Provided
Phone Number:London, England, United Kingdom
Updated August 2023. This content was crafted by an associate of Najafi Capital (“Najafi”) and is presented strictly for informational objectives. The details on this page neither advocate for nor dissuade the subscription, acquisition, or sale of any security or offering. The material Najafi evaluates for project owner screening and due diligence stems directly from the project owner presenting the investment opportunity. While Najafi perceives the information to have been sourced from trustworthy channels, there is no absolute assurance, warranty, or representation concerning its authenticity. Najafi renounces any liability regarding content provided by the project owner, inclusive of the data utilized to fulfill elements outlined on this page. Najafi is not accountable for the precision, legality, or the affirmation of subsequent details shared by the project owner.
Prospective investors are urged to perform their individual due diligence and authenticate the provided data. Investing inherently encompasses risks, inclusive of the potential loss of capital invested. All investors are recommended to ponder over these aspects in tandem with a chosen professional consultant to ascertain the suitability of an investment.
English 
Polish 